Tag:
Intradigm
Latest Headlines
Latest Headlines
Silence and Intradigm merge RNAi forces, flag deals
Two small RNAi players are merging forces in hopes of attracting some increased attention from the Big Pharma coaches calling the partnership plays. The UK's Silence Therapeutics will issue $26
Synosia raises $29M for Phase II testing
Switzerland's Synosia Therapeutics has garnered $29 million in a Series B, much of which will be spent on four experimental therapies in Phase II trials. Aravis Venture and Investor Growth Capital
Intradigm gains $18.5M in second VC round
Lilly Ventures has led an $18.5 million round for Intradigm, a Palo Alto-CA-based developer working on RNAi therapeutics. Roche Venture Fund and MP Healthcare Venture Management signed on as well
